Xponance Inc. Acquires 3,621 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Xponance Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 0.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 854,869 shares of the biopharmaceutical company’s stock after purchasing an additional 3,621 shares during the period. Xponance Inc.’s holdings in Pfizer were worth $21,662,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Norges Bank acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $2,328,986,000. Starboard Value LP acquired a new stake in Pfizer in the fourth quarter worth $407,730,000. Assenagon Asset Management S.A. increased its stake in Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock valued at $254,574,000 after purchasing an additional 7,581,030 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares in the last quarter. Finally, APG Asset Management N.V. raised its holdings in shares of Pfizer by 1,106.0% during the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after purchasing an additional 5,153,257 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.8%

Shares of NYSE:PFE opened at $25.77 on Friday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a market capitalization of $146.49 billion, a PE ratio of 18.67, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The business has a fifty day moving average price of $23.86 and a two-hundred day moving average price of $24.81. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96.

Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm’s revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.82 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.68%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of several research reports. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group raised their price objective on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Morgan Stanley upped their target price on Pfizer from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 30th. Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Finally, Redburn Atlantic lowered their price objective on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $28.55.

Get Our Latest Research Report on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).